[go: up one dir, main page]

CN1173867A - 吲哚基神经肽y受体拮抗剂 - Google Patents

吲哚基神经肽y受体拮抗剂 Download PDF

Info

Publication number
CN1173867A
CN1173867A CN96191324A CN96191324A CN1173867A CN 1173867 A CN1173867 A CN 1173867A CN 96191324 A CN96191324 A CN 96191324A CN 96191324 A CN96191324 A CN 96191324A CN 1173867 A CN1173867 A CN 1173867A
Authority
CN
China
Prior art keywords
methyl
preparation
consistent
indole
title compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN96191324A
Other languages
English (en)
Chinese (zh)
Inventor
T·C·布列顿
小R·F·布伦斯
D·R·格利特
P·A·希普斯金
K·L·劳伯
J·A·尼森
P·L·安斯坦
E·C·R·史密斯
H·扎林迈耶
D·M·兹马曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9523999.2A external-priority patent/GB9523999D0/en
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of CN1173867A publication Critical patent/CN1173867A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an alkyl or cycloalkyl radical attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CN96191324A 1995-09-01 1996-08-30 吲哚基神经肽y受体拮抗剂 Pending CN1173867A (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US315095P 1995-09-01 1995-09-01
GB9523999.2 1995-11-23
GBGB9523999.2A GB9523999D0 (en) 1995-11-23 1995-11-23 Indolyl neuropeptide y receptor antagonists
US2163896P 1996-07-12 1996-07-12
US60/003,150 1996-07-12
US08/021,638 1996-07-12

Publications (1)

Publication Number Publication Date
CN1173867A true CN1173867A (zh) 1998-02-18

Family

ID=27267993

Family Applications (1)

Application Number Title Priority Date Filing Date
CN96191324A Pending CN1173867A (zh) 1995-09-01 1996-08-30 吲哚基神经肽y受体拮抗剂

Country Status (14)

Country Link
EP (1) EP0789688A4 (fr)
CN (1) CN1173867A (fr)
AU (1) AU717422B2 (fr)
BR (1) BR9606619A (fr)
CA (1) CA2203912A1 (fr)
CZ (1) CZ132897A3 (fr)
HU (1) HUP9701714A3 (fr)
IL (1) IL120724A0 (fr)
MX (1) MX9703186A (fr)
NO (1) NO308296B1 (fr)
NZ (1) NZ318228A (fr)
PL (1) PL320010A1 (fr)
TR (1) TR199700334T1 (fr)
WO (1) WO1997009308A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105949135A (zh) * 2016-05-10 2016-09-21 湖南欧亚生物有限公司 一种赛乐西帕的合成方法
WO2016161826A1 (fr) * 2015-02-13 2016-10-13 上海适济生物科技有限公司 Procédé de préparation de 4-isopropylamino-1-butanol
CN111377821A (zh) * 2018-12-28 2020-07-07 南京艾德凯腾生物医药有限责任公司 一种合成4-异丙氨基-1-丁醇的方法

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU729590B2 (en) * 1996-10-23 2001-02-08 Sanofi-Aventis Cosmetic composition containing a neuropeptide Y receptor antagonist
EP0975584B1 (fr) * 1997-04-16 2002-09-25 Arqule, Inc. Synthese et utilisation de derives et ensembles de alpha-cetoamide
US6143931A (en) * 1997-04-16 2000-11-07 Arqule, Inc. Synthesis and use of α-ketoamide derivatives and arrays
US6337332B1 (en) 1998-09-17 2002-01-08 Pfizer Inc. Neuropeptide Y receptor antagonists
US6200990B1 (en) * 1998-12-21 2001-03-13 Alcon Laboratories, Inc. Neuroprotective agents having antioxidant and NMDA antagonist activity
AU3840000A (en) 1999-04-20 2000-11-02 Meiji Seika Kaisha Ltd. Tricyclic compounds
US6469006B1 (en) * 1999-06-15 2002-10-22 Bristol-Myers Squibb Company Antiviral indoleoxoacetyl piperazine derivatives
MXPA00006605A (es) 1999-07-02 2004-12-09 Pfizer Compuestos de carbonil-indol biciclicos como agentes antiinflamatorios/analgesicos.
EP1254115A2 (fr) 2000-02-11 2002-11-06 Bristol-Myers Squibb Company Modulateurs de recepteurs aux cannabinoides, leurs procedes de preparation et utilisations de modulateurs de recepteurs aux cannabinoides pour le traitement de maladies respiratoires et non respiratoires
EP1265607A2 (fr) * 2000-03-09 2002-12-18 Eli Lilly And Company PROCEDE DE TRAITEMENT DU DYSFONCTIONNEMENT RENAL AU MOYEN D'INHIBITEURS DE sPLA 2?
US6900226B2 (en) 2000-09-06 2005-05-31 Hoffman-La Roche Inc. Neuropeptide Y antagonists
WO2003000253A1 (fr) 2001-06-20 2003-01-03 Wyeth Derives d'acide indole substitue utilises en tant qu'inhibiteurs de l'inhibiteur-1 (pai-1) de l'activateur plasminogene
TWI224101B (en) 2001-06-20 2004-11-21 Wyeth Corp Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1)
DE60237528D1 (de) 2001-09-14 2010-10-14 High Point Pharmaceuticals Llc Neue aminoazetidin-, aminopyrrolidin- und aminopiperidinderivative
US6673829B2 (en) 2001-09-14 2004-01-06 Novo Nordisk A/S Aminoazetidine,-pyrrolidine and -piperidine derivatives
PL373410A1 (en) 2002-02-01 2005-08-22 F.Hoffman-La Roche Ag Substituted indoles as alpha-1 agonists
ATE331708T1 (de) 2002-12-10 2006-07-15 Wyeth Corp Substituierte 3-alkyl- und 3-arylalkyl-1h-indol-1-yl-essigsäure-derivate als plasminogen aktivator inhibitor-1 (pai-1) inhibitoren
UA80453C2 (en) 2002-12-10 2007-09-25 Derivatives of substituted dyhydropyranoindol-3,4-dion as inhibitors of plasminogen activator inhibitor-1 (pai-1)
BR0316584A (pt) 2002-12-10 2005-10-04 Wyeth Corp Derivados de ácido acético indol oxo-acetil amino substituìdo como inibidores do inibidor-1 do ativador do plasminogênio (pai-1)
US7078429B2 (en) 2002-12-10 2006-07-18 Wyeth Substituted 3-carbonyl-1H-indol-1-yl acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
MXPA05006283A (es) 2002-12-10 2005-08-19 Wyeth Corp Derivados de arilo, ariloxi, y alquiloxi del acido sustituido 1h-indol-3-il glicoxilico como inhibidores del inhibidor-1 activador de plasminogeno (pai-1).
WO2004054581A2 (fr) * 2002-12-13 2004-07-01 Smithkline Beecham Corporation Composes de cyclohexyle utiles en tant qu'antagonistes du ccr5
WO2004098591A2 (fr) 2003-05-05 2004-11-18 Probiodrug Ag Inhibiteurs de glutaminyl-cyclase
WO2005030754A1 (fr) * 2003-09-24 2005-04-07 Janssen Pharmaceutica, N.V. Derives d'indole ou de quinoline utilises en tant qu'inhibiteurs non-peptidiques du recepteur npy y2 pour le traitement de troubles anxiolytiques et depressifs ainsi que pour le traitement de l'obesite
US7420083B2 (en) 2003-09-25 2008-09-02 Wyeth Substituted aryloximes
US7265148B2 (en) 2003-09-25 2007-09-04 Wyeth Substituted pyrrole-indoles
US7268159B2 (en) 2003-09-25 2007-09-11 Wyeth Substituted indoles
US7351726B2 (en) 2003-09-25 2008-04-01 Wyeth Substituted oxadiazolidinediones
US7534894B2 (en) 2003-09-25 2009-05-19 Wyeth Biphenyloxy-acids
US7446201B2 (en) 2003-09-25 2008-11-04 Wyeth Substituted heteroaryl benzofuran acids
US7332521B2 (en) 2003-09-25 2008-02-19 Wyeth Substituted indoles
US7163954B2 (en) 2003-09-25 2007-01-16 Wyeth Substituted naphthyl benzothiophene acids
US7411083B2 (en) 2003-09-25 2008-08-12 Wyeth Substituted acetic acid derivatives
US7342039B2 (en) 2003-09-25 2008-03-11 Wyeth Substituted indole oximes
US7582773B2 (en) 2003-09-25 2009-09-01 Wyeth Substituted phenyl indoles
US7141592B2 (en) 2003-09-25 2006-11-28 Wyeth Substituted oxadiazolidinediones
US7442805B2 (en) 2003-09-25 2008-10-28 Wyeth Substituted sulfonamide-indoles
AU2004290499C1 (en) 2003-11-03 2011-02-24 Probiodrug Ag Combinations useful for the treatment of neuronal disorders
EP1713780B1 (fr) 2004-02-05 2012-01-18 Probiodrug AG Nouveaux inhibiteurs de la glutaminyl-cyclase
JP2008510815A (ja) 2004-08-23 2008-04-10 ワイス 血栓症および心臓血管疾患の治療にて有用な調節剤であるプラスミノゲン活性化因子阻害剤１型（ｐａｉ−１）としてのオキサゾロ−ナフチル酸
AU2005277139A1 (en) 2004-08-23 2006-03-02 Wyeth Thiazolo-naphthyl acids as inhibitors of plasminogen activator inhibitor-1
AU2005277137A1 (en) 2004-08-23 2006-03-02 Wyeth Pyrrolo-naphthyl acids as PAI-1 inhibitors
RU2007121255A (ru) 2005-01-27 2009-03-10 Вайет (Us) Способы и соединения для получения замещенных производных нафтилиндола
CA2617372A1 (fr) 2005-08-17 2007-02-22 Wyeth Indoles substitues et procedes d'utilisation de ceux-ci
WO2007046112A1 (fr) * 2005-10-19 2007-04-26 Suven Life Sciences Inc. Derives de arylthioether tryptamine utiles en tant que ligands 5-ht6 fonctionnels
EP2089383B1 (fr) 2006-11-09 2015-09-16 Probiodrug AG Dérivés 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one utiles en tant qu' inhibiteurs de la glutaminyl-cyclase dans le traitement des ulcères, du cancer et d'autres maladies
US9126987B2 (en) 2006-11-30 2015-09-08 Probiodrug Ag Inhibitors of glutaminyl cyclase
EP2481408A3 (fr) 2007-03-01 2013-01-09 Probiodrug AG Nouvelle utilisation d'inhibiteurs glutaminyle cyclase
WO2008128985A1 (fr) 2007-04-18 2008-10-30 Probiodrug Ag Dérivés de thio-urée utilisés comme inhibiteurs de la glutaminyl cyclase
PE20140858A1 (es) 2008-06-19 2014-08-04 Takeda Pharmaceutical Derivados de piperidina como inhibidores de renina
CA2772488C (fr) 2009-09-11 2018-04-17 Probiodrug Ag Derives heterocycliques en tant qu'inhibiteurs de glutaminyle cyclase
JP6026284B2 (ja) 2010-03-03 2016-11-16 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤
NZ602312A (en) 2010-03-10 2014-02-28 Probiodrug Ag Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5)
JP5945532B2 (ja) 2010-04-21 2016-07-05 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤としてのベンゾイミダゾール誘導体
EP2686313B1 (fr) 2011-03-16 2016-02-03 Probiodrug AG Dérivés de benzimidazole en tant qu'inhibiteurs de la glutaminyl cyclase
WO2012154967A1 (fr) 2011-05-12 2012-11-15 Proteostasis Therapeutics, Inc. Régulateurs de la protéostasie
EP2718464A1 (fr) 2011-06-06 2014-04-16 Imperial Innovations Limited Procédés de prédiction de l'affinité de liaison à tspo d'agents d'imagerie
ES2812698T3 (es) 2017-09-29 2021-03-18 Probiodrug Ag Inhibidores de glutaminil ciclasa

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2931323A1 (de) * 1979-08-02 1981-02-26 Kali Chemie Pharma Gmbh Neue n-aminoalkylindol-derivate und ihre salze
US5264420A (en) * 1990-09-27 1993-11-23 Merck & Co., Inc. Fibrinogen receptor antagonists
US5206382A (en) * 1991-06-27 1993-04-27 Fidia Georgetown Institute For The Neurosciences Indole derivatives, pharmaceutical compositions and methods of treating neurological and psychiatric disorders
AU665690B2 (en) * 1992-05-08 1996-01-11 Otsuka Pharmaceutical Factory, Inc. Indole derivative
TW270114B (fr) * 1993-10-22 1996-02-11 Hoffmann La Roche
IL115613A0 (en) * 1994-10-20 1996-01-19 Lilly Co Eli Bicyclic neuropeptide y receptor antagonists

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016161826A1 (fr) * 2015-02-13 2016-10-13 上海适济生物科技有限公司 Procédé de préparation de 4-isopropylamino-1-butanol
US10144701B2 (en) 2015-02-13 2018-12-04 Seasons Biotechnology (Taizhou) Co., Ltd. Method for preparing 4-isopropylamino-1-butanol
US10428012B2 (en) 2015-02-13 2019-10-01 Seasons Biotechnology Co., Ltd. Method of preparation of 4-isopropylamino-1-butanol
CN105949135A (zh) * 2016-05-10 2016-09-21 湖南欧亚生物有限公司 一种赛乐西帕的合成方法
CN111377821A (zh) * 2018-12-28 2020-07-07 南京艾德凯腾生物医药有限责任公司 一种合成4-异丙氨基-1-丁醇的方法

Also Published As

Publication number Publication date
AU6965096A (en) 1997-03-27
NO972016L (no) 1997-06-17
WO1997009308A1 (fr) 1997-03-13
PL320010A1 (en) 1997-09-01
CA2203912A1 (fr) 1997-03-13
CZ132897A3 (en) 1997-11-12
EP0789688A4 (fr) 1997-11-19
NZ318228A (en) 1999-07-29
BR9606619A (pt) 1997-12-23
TR199700334T1 (tr) 1997-08-21
HUP9701714A2 (hu) 1999-06-28
IL120724A0 (en) 1997-08-14
AU717422B2 (en) 2000-03-23
NO972016D0 (no) 1997-04-30
HUP9701714A3 (en) 2000-03-28
NO308296B1 (no) 2000-08-28
EP0789688A1 (fr) 1997-08-20
MX9703186A (es) 1997-07-31

Similar Documents

Publication Publication Date Title
CN1173867A (zh) 吲哚基神经肽y受体拮抗剂
CN1078889C (zh) 非肽类速激肽受体拮抗剂
CN1193025C (zh) 新的1,3－二氢－2h－吲哚－2－酮衍生物,它们的制备方法以及含有它们的药物组合物
CN1224623C (zh) 1－苯基磺酰基－1,3－二氢－2h－吲哚－2－酮衍生物,其制备及其治疗应用
CN1642939A (zh) 用作5－ht1f激动剂的吡啶酰基哌啶
CN1161333C (zh) 作为生长激素释放剂的2-羟基吲哚衍生物
CN1149214C (zh) 三唑并衍生物和含有它们作为有效组分的趋化因子抑制剂
CN1665502A (zh) Mchir拮抗剂
CN1599724A (zh) 咪唑－4－羧酰胺衍生物及其制备和用于治疗肥胖症的方法
CN1184425A (zh) 5－取代－3－(1,2,3,6－四氢吡啶－4－基)－和3－(哌啶－4－基)－1h－吲哚:新型5－ht1f激动剂
CN1106003A (zh) 微粒体甘油三酯转移蛋白的抑制剂和方法
CN1177844C (zh) 作为cgrp拮抗剂的新环丙烷、包含该化合物的药物及其生产方法
CN1950365A (zh) 作为肝脏－x－受体调节剂的吲哚基衍生物
CN1880304A (zh) 三酰胺取代的吲哚、苯并呋喃及苯并噻吩
CN1575284A (zh) 作为激酶抑制剂的取代的三唑二胺衍生物
CN1378533A (zh) 苯氧基丙胺类化合物
CN1143848C (zh) 用作毒蕈碱性受体拮抗剂的2-芳基乙基-(哌啶-4-基甲基)胺衍生物
CN1238760A (zh) N－(芳基/杂芳基/烷基乙酰基)氨基酸酰胺类，含有这类化合物的药物组合物，及用这类化合物抑制β－淀粉样肽释放和或合成的方法
CN1161334A (zh) 新的取代胍衍生物，其制备方法和其药物用途)
CN1777584A (zh) 作为5－ht1f激动剂的(哌啶氧基)苯基、(哌啶氧基)吡啶基、(哌啶硫基)苯基和(哌啶硫基)吡啶基化合物
CN1671386A (zh) 作为mch选择性拮抗剂的取代苯胺基哌啶
CN1427825A (zh) 吲哚满－2－酮衍生物、其制备方法及其作为催产素受体配体的应用
CN101031559A (zh) 氨基环脲衍生物和其制法及作为激酶抑制剂的医药用途
CN1993124A (zh) 取代吡唑、含有这种化合物的组合物及其应用
CN1072219C (zh) 二氮杂䓬酮、其生产和用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication